Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer : How far are we from the destination?
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Cancer medicine - 8(2019), 14 vom: 22. Okt., Seite 6403-6413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Wenhao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0W860991D6 |
|---|
| Anmerkungen: |
Date Completed 07.09.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.2384 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300847491 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300847491 | ||
| 003 | DE-627 | ||
| 005 | 20231225103410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.2384 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM300847491 | ||
| 035 | |a (NLM)31475468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luo, Wenhao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer |b How far are we from the destination? |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chemistry | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a pancreatic cancer | |
| 650 | 4 | |a prevention | |
| 650 | 7 | |a RNA, Untranslated |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a Histone Deacetylases |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 700 | 1 | |a Yang, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Jiangdong |e verfasserin |4 aut | |
| 700 | 1 | |a Luan, Jingyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a You, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Mengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Fangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yueze |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Lianfang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Taiping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yupei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 8(2019), 14 vom: 22. Okt., Seite 6403-6413 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:14 |g day:22 |g month:10 |g pages:6403-6413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.2384 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 14 |b 22 |c 10 |h 6403-6413 | ||